Literature DB >> 7762871

Comparison of case-finding methodologies for endometritis after cesarean section.

C Baker1, J Luce, C Chenoweth, C Friedman.   

Abstract

BACKGROUND: Endometritis is a possible complication of delivery among patients undergoing cesarean section, resulting in increased costs and patient morbidity. However, traditional case-finding methods for endometritis may not identify most cases. We compared various case-finding methods with a reference method to determine a simple and accurate method for collecting data on endometritis after cesarean section.
METHODS: We reviewed charts of all patients undergoing cesarean section (N = 167) during March 1 through July 31, 1991. These data were compared with study case-finding methods that used microbiology data, infection report forms from nursing, and computerized reports linking patients undergoing cesarean section with intravenous antibiotic use data and admission and discharge diagnoses.
RESULTS: Each case-finding method was compared separately with the reference method ("gold standard"), which was designed to capture all cases among the patients in the study population (N = 145). This review yielded nine cases of endometritis (infection rate of 5.4/100 procedures). The computerized report method linking patients who underwent cesarean section with antibiotic use had a positive predictive value of 0.53. Methods that used microbiology data and nursing report forms had lower positive predictive values of 0.18 and 0.20, respectively.
CONCLUSIONS: In our institution, case finding for postcesarean endometritis by means of a computerized report linking patients undergoing cesarean section with i.v. antibiotic use data and admission and discharge diagnoses is the most effective method of detecting postcesarean endometritis. It also represents the most efficient use of the infection control department's resources.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7762871     DOI: 10.1016/0196-6553(95)90005-5

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  7 in total

1.  Use of diagnosis codes and/or wound culture results for surveillance of surgical site infection after mastectomy and breast reconstruction.

Authors:  Margaret A Olsen; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

2.  Validity and Reliability of Administrative Coded Data for the Identification of Hospital-Acquired Infections: An Updated Systematic Review with Meta-Analysis and Meta-Regression Analysis.

Authors:  Olga Redondo-González; José María Tenías; Ángel Arias; Alfredo J Lucendo
Journal:  Health Serv Res       Date:  2017-04-11       Impact factor: 3.402

3.  Strategies to prevent surgical site infections in acute care hospitals: 2014 update.

Authors:  Deverick J Anderson; Kelly Podgorny; Sandra I Berríos-Torres; Dale W Bratzler; E Patchen Dellinger; Linda Greene; Ann-Christine Nyquist; Lisa Saiman; Deborah S Yokoe; Lisa L Maragakis; Keith S Kaye
Journal:  Infect Control Hosp Epidemiol       Date:  2014-06       Impact factor: 3.254

4.  The Impact of a Reported Penicillin Allergy on Surgical Site Infection Risk.

Authors:  Kimberly G Blumenthal; Erin E Ryan; Yu Li; Hang Lee; James L Kuhlen; Erica S Shenoy
Journal:  Clin Infect Dis       Date:  2018-01-18       Impact factor: 9.079

Review 5.  Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section.

Authors:  Fiona M Smaill; Rosalie M Grivell
Journal:  Cochrane Database Syst Rev       Date:  2014-10-28

Review 6.  Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section.

Authors:  Fiona M Smaill; Gillian Ml Gyte
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

7.  Electronically assisted surveillance systems of healthcare-associated infections: a systematic review.

Authors:  H Roel A Streefkerk; Roel Paj Verkooijen; Wichor M Bramer; Henri A Verbrugh
Journal:  Euro Surveill       Date:  2020-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.